Navigation Links
WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
Date:1/10/2010

SHANGHAI, Jan. 10 /PRNewswire-Asia/ -- WuXi AppTec Inc. today announced that it has entered into a partnership with QIAGEN to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases. QIAGEN will provide a complete portfolio of instrumentation, training, and consumables and WuXi AppTec will provide laboratory facilities and staff to execute the services. The laboratory will be located at WuXi AppTec's campus in Shanghai and will begin operating immediately.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Under the terms of the partnership agreement, WuXi AppTec will also work with QIAGEN to help develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that QIAGEN intends to bring to market. WuXi AppTec will use QIAGEN's technologies for a broad range of applications in support of drug discovery and development on behalf of the company's and QIAGEN's customers. WuXi AppTec and QIAGEN will also co-promote each other's services to their respective customers. Both companies are working closely to identify additional opportunities to deepen their relationship.

"WuXi AppTec has long been interested in partnering with a premier international molecular biotechnology company like QIAGEN to support the development of our biomarker business," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This partnership gives us access to innovative technologies and processes that will allow us to better serve our customers."

"We are very pleased to have entered into this partnership with WuXi AppTec, a global leader in providing integrated research and development services to the pharmaceutical industry," said Dr. Victor Shi, President, Asia Pacific of QIAGEN. "In doing so, we have created what we believe to be the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery and development and molecular diagnostics in personalized healthcare and other areas. We believe that this partnership is a significant milestone in providing high-quality and complete automated solutions for the molecular biomarker testing industry."

About WuXi AppTec:

WuXi AppTec is a leading pharmaceutical, biotechnology, and medical-device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services throughout the pharmaceutical and medical-device R&D process. WuXi AppTec's services are designed to help its global partners to improve the success, shorten the time, and reduce the cost of research and development.

Web: http://www.wuxiapptec.com .

About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digeneHPV Test, which is regarded as a "gold standard" in testing for high- risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

    For further information, please contact:

    WuXi AppTec Inc.
    Ronald Aldridge
    Director of Investor Relations
    Tel:   +1-201-585-2048
    Email: Ron_Aldridge@wuxiapptec.com

SOURCE WuXi AppTec Inc.

RELATED LINKS
http://www.wuxiapptec.com
http://www.qiagen.com/

'/>"/>

SOURCE WuXi AppTec Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
2. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
3. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
4. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
5. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
6. University of Pittsburgh Medical Center (UPMC) Treats 10,000th Patient with Leksell Gamma Knife Radiosurgery System
7. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
8. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
9. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
10. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
11. Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):